ECE2022 Eposter Presentations Thyroid (219 abstracts)
1Faculty of Dental Medicine and Health and Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia; 2School of Medicine, University of Zagreb, Zagreb, Croatia; 3Clinical Hospital Sveti Duh, Zagreb, Croatia; 4Center for Cancer Medicine, Oslo, Norway
Purpose: Papillary thyroid cancer (PTC) is the most common thyroid and endocrine malignancy worldwide. Vitamin D (calciferol or 25-hydroxyvitamin D) (25(OH)D) has been postulated as a key modulator in several cancer-related pathways, although its contribution to PTC still remain controversial. The aim of the study was to analyse the correlation between 25(OH)D serum levels and 25(OH)D insufficiency as well as the risk of development of PTC and its variants: classical type (CV-PTC), tall cell type (TCV-PTC) and follicular variant (FV-PTC).
Methods: The study included 259 patients: 112 patients diagnosed with PTC (CV-PTC, n = 78; TCV-PTC, n = 8; FV-PTC, n = 26), and 147 patients diagnosed with benign thyroid nodules, all aged 43-71±7 years. Diagnosis of the PTC and its variants was confirmed with cyto/histopathological examination. The serum levels of 25(OH)D were measured by fully automated chemiluminescentmicroparticle immunoassay (CMIA). 25(OH)D insufficiency was defined as a serum 25(OH)D level <75 nmol/l.
Results: The prevalence of 25(OH)D insufficiency was 38.2%. Serum 25(OH)D levels and the prevalence of 25(OH)D insufficiency showed no significant differences between both group of patients (P=0.65). Among PTC patients, 25(OH)D insufficiency was not associated with any PTC subtype or other clinical manifestation (P=0.87).
Conclusions: This study shows no association of 25(OH)D insufficiency with the development of PTC, different PTC subvariants or any other clinical characteristic of PTC.